Working… Menu

Tocilizumab in Patients With Schnitzler's Syndrome (TOCISCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03046381
Recruitment Status : Recruiting
First Posted : February 8, 2017
Last Update Posted : January 31, 2019
Roche Pharma AG
Information provided by (Responsible Party):
Karoline Krause, Charite University, Berlin, Germany

Brief Summary:

Schnitzler's Syndrome (SchS) is a late-onset multifactorial autoinflammatory disease characterized by chronic urticarial skin lesions and a monoclonal gammopathy usually belonging to the immunoglobulin M (IgM) or IgG class. Symptoms associated with SchS are recurrent fever attacks, bone and muscle pain, arthralgia or arthritis, fatigue and lymphadenopathy. SchS is a rare disease with approximately 300 cases reported in the literature. The nature of SchS is chronic without known reports about spontaneous remissions. Disease onset occurs around the age of 50. About 15% of patients eventually develop a lymphoproliferative disorder, most often Waldenström's macroglobulinemia. The pathogenesis of SchS is still not well defined. Functional ex vivo studies showed excessive cytokine production (IL-1ß, IL-6 and IL-18) of peripheral blood monocytes (PBMCs) in SchS as compared to healthy controls. In addition to excessive IL-6 secretion from PBMCs IL-6 has repeatedly been reported to be elevated in the serum of SchS patients too. As IL-6 plays a major role in the development of multiple myeloma, IL-6 may also be associated with the formation of lymphoproliferative disorders in SchS.

Until now, there is no approved standard therapy available for the treatment of SchS. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and other immunosuppressive agents have been reported to provide variable relief from symptoms of bone pain and arthralgia. Case reports and small studies about successful treatment of SchS with anti-IL-1 blockers (anakinra, rilonacept and canakinumab) accumulate. However, there have been complete and partial treatment failures to anti-IL-1 blockade in SchS. In these patients, anti-IL-6 treatment (tocilizumab [TCZ]) demonstrated to be very effective in reducing the clinical symptoms and inflammation markers in SchS. TCZ treatment has proved to be very effective, well-tolerated and safe in other acquired autoinflammatory disorders, systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease that share many clinical features (rash, fever, joint involvement, lymphadenopathy, fatigue) and excessive cytokine production with SchS. The study consists of a run-in baseline period of 1-4 weeks followed by an open-label 20-week TCZ treatment phase with weekly s.c. injections (TCZ 162mg), followed by an optional study extension up to a total of 1 year with ongoing once weekly TCZ 162mg injections and a 4 week period of follow-up.

Condition or disease Intervention/treatment Phase
Schnitzler's Syndrome Drug: Tocilizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Open-label Study to Assess the Efficacy and Safety of Tocilizumab in Patients With Active Schnitzler's Syndrome
Actual Study Start Date : July 19, 2017
Estimated Primary Completion Date : July 31, 2019
Estimated Study Completion Date : July 31, 2019

Arm Intervention/treatment
Tocilizumab 162mg 1x weekly as subcutaneous syringe
Drug: Tocilizumab
Tocilizumab 162mg 1x weekly s.c.
Other Name: RoActemra®

Primary Outcome Measures :
  1. Physician global assessment [ Time Frame: Baseline vs. week 20 ]
    Change in the investigator's assessment of total disease activity (physician global assessment [PGA]) between baseline and TCZ Treatment

Secondary Outcome Measures :
  1. Complete responders [ Time Frame: Week 20 ]
    Proportion of patients with complete response (based on PGA with no or minimal overall autoinflammatory disease activity and CRP </= 10 mg/l)

  2. Schnitzler Activity Score [ Time Frame: 60 weeks ]
    Change in the patient based Schnitzler Activity Score (SchAS) during the treatment period (The SchAS combines the key symptoms of SchS).

  3. Inflammation marker CRP [ Time Frame: 60 weeks ]
    Change in CRP levels during the treatment period

  4. Inflammation marker SAA [ Time Frame: 60 weeks ]
    Change in SAA levels during the treatment period

  5. Inflammation marker S100 A8/9 [ Time Frame: 60 weeks ]
    Change in S100 A8/9 levels during the treatment period

  6. Overall quality of life [ Time Frame: 60 weeks ]
    Change in the patient's quality of life (assessed by the SF-36)

  7. Dermatology-specific quality of life [ Time Frame: 60 weeks ]
    Change in the patient's quality of life (assessed by the Dermatology Life Quality Index)

  8. Safety and tolerability assessed by adverse event reporting over the whole study period [ Time Frame: 60 weeks ]
    Adverse event reporting over the whole study period

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults (18 years or older)
  • SchS diagnosis based on Strasbourg clinical criteria
  • Active SchS, refractory to treatment with antihistamines, NSAIDS or colchicine, hydroxychloroquine or dapsone
  • Patients who have a symptom score (PGA) of at least 8 (0-20) at baseline
  • If necessary, concurrent/ongoing treatment with a stable dose of systemic corticosteroids not greater than 10mg/d for 14 days prior to screening
  • If necessary, concurrent/ongoing treatment with a stable dose of antihistamines and NSAIDs for 7 days prior to screening
  • Able to read, understand and willing to sign the informed consent form and abide with study procedures
  • Willing, committed and able to return for all clinic visits and complete all study-related procedures, including willingness to have SC injections administered by a qualified person
  • In females of childbearing potential: Negative pregnancy test within 28 days of randomization; males and females willing to use highly effective contraception (Pearl-Index < 1) during study treatment and for a minimum of 3 months after last dose of TCZ. Pregnancies occurring up to 90 days after the completion of the study medication must be reported to the investigator. A woman will be considered not of childbearing potential if she is post-menopausal for greater than two years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)
  • Subjects are considered eligible, if they meet the following tuberculosis (TB) screening criteria: no history of latent or active TB prior to screening, no signs or symptoms suggestive of active TB, no recent close contacts with a person with active TB, and negative QuantiFERON-TB test at screening (if QuantiFERON-TB test is positive, the patient can only be included if active TB is ruled out with appropriate measurements according to standard of care, e.g. the patient is pre-treated with isoniazide for 4 weeks).
  • No participation in other clinical trials 4 weeks before and after participation in this study

Exclusion criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
  • Concurrent/ongoing treatment with biologics or recent treatment (less than 5 half lives)

    • With Anakinra within 7 days prior to screening, with canakinumab within 100 days prior to screening
    • with oral/parental corticosteriods greater than 10 mg/d within 2 weeks prior to screening
    • with Cyclosporin A Methotrexate, Dapsone, Chloroquine, Hydroxychloroquine, Azathioprine, Cyclophosphamide within 4 weeks prior to screening
    • other immunosuppressives within 4 weeks or 5 half lives prior to screening, whichever is longer
    • Previous treatment within six months of randomization with any cell-depleting therapies, including investigational agents or approved therapies, some examples include: CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20.
    • Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline.
  • Treatment with a live (attenuated) virus vaccine within 4 weeks prior to Baseline visit
  • Significant medical condition rendering the patient immunocompromised or not suitable for a clinical trial
  • Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
  • History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
  • An abnormal chest radiograph consistent with clinical signs of prior or present tuberculosis infection whether or not previously treated with anti-tuberculosis agents
  • Significant concomitant illness such as, but not limited to, cardiac, renal, neurological, endocrinological, metabolic, or lymphatic disease that would adversely affect the subject's participation or evaluation in this study
  • Evidence of current HIV, Hepatitis B, or Hepatitis C infection by clinical or serological history
  • Presence of any of the following laboratory abnormalities at enrollment visit: serum creatinine > 1.6 mg/dL (141 µmol/L) in female patients and > 1.9 mg/dL (168 µmol/L) in male patients, WBC <3,000/µl; platelet count <100000/µl ; ALT or AST >2 x ULN or total bilirubin >ULN, Hemoglobin <8.0 g/dL, neutrophil count <2,000 cells/µl or lymphocyte count <500/ µl
  • Evidence of active, recurrent or latent systemic infection
  • Active systemic inflammatory condition other than SchS including, but not limited to, rheumatoid arthritis
  • History of malignancies within five years prior to screening other than a successfully treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ cervical cancer
  • Lactating females or pregnant females
  • Enrollment in another investigational treatment or device study or use of an investigational agent, or less than 4 weeks or 5 half-lives, whichever is longer, since end of another investigational device or drug trial
  • Subjects for whom there is concern about compliance with the protocol procedures
  • Any medical condition which, in the opinion of the Investigator, would interfere with participation in the study or place the subject at risk
  • History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) that could limit the subject's ability to comply with study procedures.
  • Patients with known hypersensitivity to tocilizumab

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03046381

Layout table for location contacts
Contact: Karoline Krause, MD +49 30 450 518 ext 336
Contact: Marcus Maurer, MD +49 30 450 518 ext 042

Layout table for location information
Charité - Universitätsmedizin Berlin, Dpt. of Dermatology and Allergy Recruiting
Berlin, Germay, Germany, 10117
Contact: Karoline Krause, MD    +49 30 450 518 ext 336   
Contact: Hanna Bonnekoh, MD    +49 30 450 618 ext 077   
Sponsors and Collaborators
Karoline Krause
Roche Pharma AG
Layout table for investigator information
Principal Investigator: Karoline Krause, MD Charite University, Berlin, Germany

Layout table for additonal information
Responsible Party: Karoline Krause, Principal Investigator, Charite University, Berlin, Germany Identifier: NCT03046381     History of Changes
Other Study ID Numbers: TOCISCH
First Posted: February 8, 2017    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Schnitzler Syndrome
Pathologic Processes
Monoclonal Gammopathy of Undetermined Significance
Immunoproliferative Disorders
Immune System Diseases